JPMorgan keeps EUR 55.20 target for Fresenius stock ahead of results

Published on 10/27/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock costs EUR 46.32 on October 27, 2026, below the EUR 46.45 Xetra close. Second-quarter organic revenue rose 6.00 percent year over year.

Target, earnings and timing

JPMorgan maintained an Overweight rating and a EUR 55.20 target on October 26, 2026.
Fresenius reported second-quarter 2026 organic revenue of EUR 5.864 billion, up 6.00 percent.
Fresenius stock traded at EUR 46.32 at 10:04 a.m. CET at Lang & Schwarz on October 27, 2026, 0.28 percent below the Xetra close of October 26, 2026.
Fresenius is scheduled to report third-quarter 2026 results on November 4, 2026.

Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) traded at EUR 46.32 at Lang & Schwarz on October 27, 2026 at 10:04 a.m. CET, 0.28 percent below the Xetra close of October 26, 2026 at EUR 46.45. JPMorgan kept its Overweight rating and EUR 55.20 price target on October 26, 2026, ahead of the company's third-quarter results.

JPMorgan sets the near-term test

According to Börse Online on October 26, 2026, analyst David Adlington expects Fresenius revenue for the upcoming quarter to be 1.60 percent above consensus, while adjusted operating profit is expected to match consensus. The note described the expected report as good and identified Fresenius as JPMorgan's sector favorite.

The target of EUR 55.20 stands 19.16 percent above the Lang & Schwarz price of EUR 46.32. That comparison makes the November report the next measurable test for the analyst's view, although the target is not a forecast from this article.

Three milestones shape the story

On August 5, 2026, Fresenius reported second-quarter organic revenue growth of 6.00 percent to EUR 5.864 billion and group EBIT of EUR 719 million, up 10.00 percent at constant currency, according to Fresenius. On September 30, 2026, the company completed its acquisition of the remaining 45 percent of mAbxience for consideration of up to EUR 750 million, as reported by Placera. The October 26, 2026 JPMorgan note is the latest of the three events.

What does the deal add?

Full ownership gives Fresenius Kabi control of the mAbxience biosimilars platform from development through commercialization. The transaction was expected to contribute immediately to adjusted earnings per share, while the company said its 2026 outlook and 2030 biopharma ambition were unchanged.

Next reporting date is November 4

Börse Online identified November 4, 2026 as the date for Fresenius's third-quarter results. The release will show whether the revenue outlook cited by JPMorgan translates into reported growth and whether adjusted operating profit meets consensus.

Stock stays below its yearly high

Fresenius stock remains EUR 6.64 below its 52-week high of EUR 52.96, a gap of 12.54 percent based on the same market snapshot. The current quote points to a modest intraday move, while the analyst target and the scheduled results provide the clearest dated reference points for the next phase.

Fresenius stock was trading at EUR 46.32 at Lang & Schwarz on October 27, 2026 at 10:04 a.m. CET, 0.28 percent below the Xetra close of October 26, 2026 at EUR 46.45. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.